Research Topics
Species | James W VardimanSummaryAffiliation: University of Chicago Country: USA Publications
| Collaborators
|
Detail Information
Publications
A Subset of Rosai-Dorfman Disease Exhibits Features of IgG4-Related DiseaseXuefeng Zhang
Dept of Pathology, University of Chicago Medical Center, Hematopathology Section TW055C, MC0008, 5841 South Maryland Ave, Chicago, IL 60637 e mail
Am J Clin Pathol 139:622-32. 2013..These findings demonstrate that a subset of RDD shows features of IgG4-related disease and indicate an overlap between certain aspects of the 2 diseases...- The classification of MDS: from FAB to WHO and beyondJames Vardiman
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Leuk Res 36:1453-8. 2012..This paper outlines the evolution from the FAB to the WHO classification of MDS and gives a glimpse of what might lie beyond... - World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variantsJames Vardiman
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Hematology Am Soc Hematol Educ Program 2011:250-6. 2011..An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis... - The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasmsJames W Vardiman
University of Chicago Medical Center, 5841 South Maryland Avenue, MC0008, Chicago, IL 60637, United States
Chem Biol Interact 184:16-20. 2010.... - The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesJames W Vardiman
Department of Pathology, University of Chicago, IL, USA
Blood 114:937-51. 2009.... 
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevantZeba N Singh
Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Am J Clin Pathol 127:197-205. 2007..We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis...- The World Health Organization (WHO) classification of the myeloid neoplasmsJames W Vardiman
Department of Pathology, University of Chicago, IL 60637, USA
Blood 100:2292-302. 2002.... - Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock
University of Chicago, Illinois, USA
Cancer 119:90-8. 2013.... - Myelodysplastic/myeloproliferative neoplasmsElizabeth Hyjek
Department of Pathology, Hematopathology Section, University of Chicago, Chicago, Illinois, USA
Semin Diagn Pathol 28:283-97. 2011..In this review we will give an overview of these neoplasms and focus on adult MDS/MPN, especially CMML. We will give only brief updates for aCML and RARS-T; JMML will be discussed in a separate article... - Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseasesJames W Vardiman
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Semin Diagn Pathol 20:154-79. 2003..It is hoped that when an excellent specimen is available, the guidelines contained in this article may provide the pathologist with assistance in arriving at the most appropriate diagnosis... - The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MDJames W Vardiman
Department of Pathology, University of Chicago, Illinois, USA
Clin Adv Hematol Oncol 1:18, 21. 2003 - Myelodysplastic/myeloproliferative diseasesJames W Vardiman
University of Chicago, Department of Pathology, Chicago, Illinois, USA
Cancer Treat Res 121:13-43. 2004 - Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesSonali M Smith
Section of Hematology/Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Blood 102:43-52. 2003..0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML... 
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock
Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
Blood 112:1646-54. 2008..Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated...- The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cellsOzden Ozer
Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
Leuk Lymphoma 49:1567-77. 2008..Our discovery of novel KIT transcripts underscores the importance of analysing entire protein encoding regions when studying genes of interest...